


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



四环医药
SihuanPharm

Sihuan Pharmaceutical Holdings Group Ltd.

四環醫藥控股集團有限公司

(incorporated in Bermuda with limited liability)

(Stock Code: 0460)

**VOLUNTARY ANNOUNCEMENT
XUANZHU BIOPHARM COMPLETED PATIENT
ENROLLMENT IN PHASE II CLINICAL TRIALS ON
NEW INDICATION OF INDEPENDENTLY DEVELOPED DRUG
ANAPRAZOLE SODIUM**

The board of directors (the “**Board**”) of Sihuan Pharmaceutical Holdings Group Ltd. (the “**Company**” or “**Sihuan Pharmaceutical**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Group’s non-wholly owned subsidiary Xuanzhu Biopharmaceutical Co., Ltd. (“**Xuanzhu Biopharm**”) has completed all patient enrollment of Anaprazole Sodium enteric solution tablets, its independently developed drug, in phase II clinical trials for the treatment in new indication of reflux esophagitis (RE) and its associated symptoms (acid reflux, heartburn, retrosternal pain or discomfort, belching reflux, etc.) control in adults. Xuanzhu Biopharm plans to initiate phase III clinical trials of the same indication by the end of 2023.

Anaprazole Sodium is the only new generation proton pump inhibitor (“**PPI**”) independently developed in China, and its first indication for the treatment of duodenal ulcer has submitted for new drug application (NDA) in 2021. Anaprazole Sodium is metabolised by multiple enzymes and non-enzymes, and has a low risk of drug interaction, and significant clinical advantages.

According to IQVIA data, the market size of PPI drugs in China in 2021 exceeded RMB20 billion, of which oral preparations reached RMB10 billion. RE is a common disease of the digestive system with a prevalence rate of 6.4% in the general population in China. PPI is often used in clinical practice to treat RE, with significant therapeutic effects and effective improvement of symptoms such as pain, acid reflux and heartburn, and has significant clinical applications.

About Xuanzhu Biopharm

Xuanzhu Biopharmaceutical is the innovative drug subsidiary of Sihuan Pharmaceutical. It is an innovative pharmaceutical company with roots in China and a global perspective, focusing on major diseases such as digestion, oncology and non-alcoholic steatohepatitis, and is committed to the continuous research and development, production and commercialization of class 1 drugs with core proprietary intellectual property rights to address unmet clinical medical needs. The company has a team with extensive experience in the development and industrialisation of innovative drugs. Having been involved in the research of digestion, oncology and non-alcoholic steatohepatitis for many years, the company has a deep understanding and international vision of the development of new drugs in related fields and their future development direction. The company has two R&D platforms: small molecule chemistry and large molecule biologics. The dual engines drive the company's innovation and development, forming a product pipeline that covers small molecule, monoclonal antibodies, bispecific antibodies, antibody-drug conjugate (ADC) and other types of products. The company adheres to the strategic concept of "innovation driven, promoting the development of new drugs in China and serving human health", and the values of "open innovation, courageous commitment, overcoming difficulties and scientific rigor". With a focus on unmet clinical needs, the company continues to develop new class 1 drugs with international competitiveness, and is committed to developing into a first-class innovative pharmaceutical company with independent research and development, production, and sales capabilities.

About Sihuan Pharmaceutical

Founded in 2001 and listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2010, Sihuan Pharmaceutical is an international medical aesthetic and biopharmaceutical company led and driven by innovation, with an independent and leading research and development technology platform, a rich global product pipeline, strong product registration capability, a full dosage form production platform with high efficiency and low cost and a mature and excellent sales system. Adhering to the overall strategic objective of "full promotion of a two-wheel drive strategy of its medical aesthetics and biopharmaceutical businesses", Sihuan Pharmaceutical endeavours to build itself into a leading medical aesthetics and biopharmaceutical company in China.

This announcement is being made by the Group on a voluntary basis to update the investing public on the Group's latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medicine, surgical appliance, treatment or orally consumed product.

By order of the Board
Sihuan Pharmaceutical Holdings Group Ltd.
Dr. Che Fengsheng
Chairman and Executive Director

Hong Kong, 18 April 2023

As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong, Ms. Chen Yanling and Ms. Miao Guili; and the independent non-executive directors of the Company are Mr. Tsang Wah Kwong, Dr. Zhu Xun and Mr. Wang Guan.